Biotech Values

[Mufaso]

LLY-NVO-VKTX- While NVO has a great position today, it is Lilly that is really shining with Orfroglipron (a daily oral GLP-1) and Retatrutide (an injectable GIP/GLP-1/Glucagon Receptor Triagonist). The phase 2 results for both of these drugs are very impressive. That combined with Lilly's current injectable Mounjaro makes Lilly look like a winner.

Info on both drugs:
https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-research-treatment-diabetes-and-obesity

Here is additional info on Retatrutide:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext#back-bib1

The jury is out on whether VKTX may be able to compete with its dual GLP-1/GIP compound. Phase VK2809 results at 12 weeks were impressive for VK2809 as an injectable. They are currently running a phase 1 oral study for this compound and have are looking to start phase 2 on this drug as an injectable. Results for LLY's new drugs are at 26 weeks and no 26-week data is available for Vikings drug yet. The fact that VK2809 does not have activity for glucagon may make it safer than Retatrutide and as an oral, we may find out it is more effective than Orfroglipron.